In recent years, congressional hearings have often featured intense questioning of pharmaceutical company CEOs regarding the high costs of prescription drugs. These hearings allow policymakers to express their concerns about rising drug prices and hold pharmaceutical executives accountable for their pricing practices. However, despite the scrutiny and public outcry, these hearings have had limited impact on lowering drug prices. In this blog post, we’ll explore why this is the case.

Diabetes, often referred to as the silent killer, is a chronic disease that affects millions worldwide. Despite its prevalence and potentially severe consequences, many individuals remain unaware of the risks and symptoms associated with this condition. The lack of awareness surrounding diabetes is a significant public health concern, contributing to delayed diagnosis, inadequate management, and an increased burden on healthcare systems. Understanding why people don’t know about the risks and symptoms of diabetes is crucial in addressing this pervasive issue.

Whether the FDA (Food and Drug Administration) should protect online health seekers from false information is complex and nuanced. While the FDA plays a crucial role in regulating the safety and efficacy of drugs, medical devices, and other healthcare products, its jurisdiction primarily extends to products marketed and sold within the United States. However, the FDA’s authority over online health information is limited, especially when it comes to content disseminated by individuals or entities outside the jurisdiction of the United States.

Direct-to-consumer (DTC) marketing has long been a cornerstone of pharma companies’ strategies to connect with patients and promote their products. However, in recent years, a growing number of senior managers in the pharma industry have expressed concerns and have lost confidence in the effectiveness of DTC marketing. This shift in perception is driven by a confluence of factors that challenge the traditional approaches to reaching consumers and building trust. In this blog post, we will explore the reasons behind the erosion of confidence in pharma DTC marketing among senior managers.

In recent years, the airwaves have become saturated with pharma commercials, showcasing the wonders of newly developed drugs and their potential to transform lives. These advertisements, often accompanied by vibrant visuals and heartwarming narratives, aim to create a direct link between the viewer and the miraculous solutions offered by modern medicine. However, a growing disparity has emerged between the captivating promises of these ads and the reality of patients actively seeking these prescriptions from their healthcare providers. This disconnect raises essential questions about the effectiveness and ethics of pharma advertising.